Duration of cisplatin excretion in breast milk

J Hum Lact. 2013 Nov;29(4):469-72. doi: 10.1177/0890334413479671. Epub 2013 Mar 14.

Abstract

Cisplatin, a platinum-based chemotherapy agent, is commonly used in treating cancers that may affect women of childbearing age, including cervical cancer, triple-negative breast cancer, and pediatric tumors in adolescents. The authors found that platinum was undetectable in breast milk at 66 hours and beyond following a 70-mg dose of intravenous cisplatin. Relative infant dose of platinum was calculated to be between 0.29% and 0.40% of the maternal dose corrected for body weight. This case demonstrates minimal exposure to platinum via breast milk, following a single 70-mg intravenous dose of cisplatin.

Keywords: breast milk; breastfeeding; cisplatin; human milk.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adult
  • Breast Feeding*
  • Cisplatin / analysis*
  • Cisplatin / pharmacokinetics*
  • Cisplatin / therapeutic use
  • Female
  • Humans
  • Infant
  • Milk, Human / chemistry*
  • Time Factors
  • Uterine Cervical Neoplasms / drug therapy

Substances

  • Cisplatin